Diffuse membranous immunoreactivity for podoplanin (D2-40) distinguishes primary and metastatic seminomas from other germ cell tumors and metastatic neoplasms

American Journal of Clinical Pathology

Volumn 128, Issue 5, 2007, Pages 767-775

  Yu, Hongbo ^a   Pinkus, Geraldine S ^a   Hornick, Jason L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

D2 40; Germ cell tumors; Immunohistochemistry; Podoplanin; Seminoma

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY D2 40; PODOPLANIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; GERM CELL TUMOR; HUMAN; IMMUNODETECTION; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SEMINOMA;

ANTIBODIES, MONOCLONAL; CELL MEMBRANE; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MEMBRANE GLYCOPROTEINS; NEOPLASM PROTEINS; SEMINOMA; SENSITIVITY AND SPECIFICITY; TESTICULAR NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 36248973158     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/4GMREAULY257R3AY     Document Type: Article

References (38)

1. Breiteneder-Geleff S, Matsui K, Soleiman A, et al. Podoplanin, novel 43-kd membrane protein of glomerular epithelial cells, is down-regulated in puromycin nephrosis. Am J Pathol. 1997;151:1141-1152.
2. Ordonez NG. Podoplanin: a novel diagnostic immunohistochemical marker. Adv Anat Pathol. 2006;13:83-88.
3. Schacht V, Ramirez MI, Hong Y-K, et al. T1a/podoplanin deficiency disrupts normal lymphatic vasculature formation and causes lymphedema. EMBO J. 2003;22:3546-3556.
4. Schacht V, Dadras SS, Johnson LA, et al. Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. Am J Pathol. 2005;166:913-921.
5. Sugimoto Y, Watanabe M, Oh-hara T, et al. Suppression of experimental lung colonization of a metastatic variant of murine colon adenocarcinoma 26 by a monoclonal antibody 8F11 inhibiting tumor cell-induced platelet aggregation. Cancer Res. 1991;51:921-925.
6. Watanabe M, Okochi E, Sugimoto Y, et al. Identification of a platelet-aggregating factor of murine colon adenocarcinoma 26: Mr 44,000 membrane protein as determined by monoclonal antibodies. Cancer Res. 1988;48:6411-6416.
7. Kato Y, Fujita N, Kunita A, et al. Molecular identification of Aggrus/T1a as a platelet aggregation-inducing factor expressed in colorectal tumors. J Biol Chem. 2003; 278:51599-51605.
8. Kato Y, Sasagowa I, Kaneko M, et al. Aggrus: a diagnostic marker that distinguishes seminoma from embryonal carcinoma in testicular germ cell tumors. Oncogene. 2004;23:8552-8556.
9. Marks A, Sutherland DR, Bailey D, et al. Characterization and distribution of an oncofetal antigen (M2A antigen) expressed on testicular germ cell tumors. Br J Cancer. 1999;80:569-578.
10. Garner MJ, Turner MC, Ghadirian P, et al. Epidemiology of testicular cancer: an overview. Int J Cancer. 2005;116:331-339.
11. Bosl GJ, Motzer RJ. Testicular germ-cell cancer. N Engl J Med. 1997;337:242-253.
12. Einhorn LH. Treatment of testicular cancer: a new and improved model. J Clin Oncol. 1990;8:1777-1781.
13. Sung MT, MacLennan GT, Cheng, L. Retroperitoneal seminoma in limited biopsies: morphologic criteria and immunohistochemical findings in 30 cases. Am J Surg Pathol. 2006;30:766-773.
14. Biermann K, Klingmuller D, Koch A, et al. Diagnostic value of markers M2A, OCT3/4, AP-2γ, PLAP and c-KIT in the detection of extragonadal seminomas. Histopathology. 2006;49:290-297.
15. Woodward PJ, Heidenreich A, Looijenga LHJ, et al. Germ cell tumors. In: Eble JN, Sauter G, Epstein JI, et al, eds. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon, France: IARC Press; 2004:221-250. World Health Organization Classification of Tumours.
16. Bailey D, Marks A, Stratis M, et al. Immunohistochemical staining of germ cell tumors and intratubular malignant germ cells of the testis using antibody to placental alkaline phosphatase and a monoclonal anti-seminoma antibody. Mod Pathol. 1991;4:167-171.
17. Burke AP, Mostofi FK. Placental alkaline phosphatase immunohistochemistry of intratubular malignant germ cells and associated testicular germ cell tumors. Hum Pathol. 1988;19:663-670.
18. Hattab EM, Tu PH, Wilson JD, et al. OCT4 immunohistochemistry is superior to placental alkaline phosphatase (PLAP) in the diagnosis of central nervous system germinoma. Am J Surg Pathol. 2005;29:368-371.
19. Looijenga LH, Stoop H, de Leeuw HP, et al. POU5F1 (OCT3/4) identifies cells with pluripotent potential in human germ cell tumors. Cancer Res. 2003;63:2244-2250.
20. Jones TD, Ulbright TM, Eble JN, et al. OCT4: a sensitive and specific biomarker for intratubular germ cell neoplasia of the testis. Clin Cancer Res. 2004;10:8544-8547.
21. Jones TD, Ulbright TM, Eble JN, et al. OCT4 staining in testicular tumors: a sensitive and specific marker for seminoma and embryonal carcinoma. Am J Surg Pathol. 2004;28:935-940.
22. Jong JD, Stoop H, Dohle GR, et al. Diagnostic value of OCT3/4 for pre-invasive and invasive testicular germ cell tumors. J Pathol. 2005;206:242-249.
23. Cheng L. Establishing a germ cell origin for metastatic tumors using OCT4 immunohistochemistry. Cancer. 2004;101:2006-2010.
24. Bailey D, Baumal R, Law J, et al. Production of a monoclonal antibody specific for seminomas and dysgerminomas. Proc Natl Acad Sci U S A. 1986;83:5291-5295.
25. Sonne SB, Herlihy AS, Hoei-Hansen CE, et al. Identity of M2A (D2-40) antigen and gp36 (Aggrus, TIA-2, podoplanin) in human developing testis, testicular carcinoma in situ and germ-cell tumours. Virchows Arch. 2006;449:200-206.
26. Sesterhenn IA, Davis CJ, Furusato B. M2A antigen (podoplanin) distribution in prepubertal and adult testes and testicular tumors [abstract]. Mod Pathol. 2006;19(suppl 1):159A-160A.
27. Ordonez NG. The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: a comparative study. Mod Pathol. 2006;19:34-38.
28. Ordonez NG. The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: a comparative study. Mod Pathol. 2006;19:417-428.
29. Roy S, Chu A, Trojanowski JQ, et al. D2-40, a novel monoclonal antibody against the M2A antigen as a marker to distinguish hemangioblastomas from renal cell carcinomas. Acta Neuropathol. 2005;109:497-502.
30. Liang H, Wu H, Giorgadze TA, et al. Podoplanin is a highly sensitive and specific marker to distinguish primary skin adnexal carcinomas from adenocarcinomas metastatic to skin. Am J Surg Pathol. 2007;31:304-310.
31. Bassarova AV, Nesland JM, Davidson B. D2-40 is not a specific marker for cells of mesothelial origin in serous effusions. Am J Surg Pathol. 2006;30:878-882.
32. Chu AY, Litzky LA, Pasha TL, et al. Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma. Mod Pathol. 2005;18:105-110.
33. Ordonez NG. D2-40 and podoplanin are highly specific and sensitive immunohistochemical markers of epithelioid malignant mesothelioma. Hum Pathol. 2005;36:372-380.
34. Ordonez NG. Immunohistochemical diagnosis of epithelioid mesothelioma: an update. Arch Pathol Lab Med. 2005;129:1407-1414.
35. Muller AM, Franke FE, Muller KM. D2-40: a reliable marker in the diagnosis of pleural mesothelioma. Pathobiology. 2006;73:50-54.
36. Mimura T, Ito A, Sakuma T, et al. Novel marker D2-40, combined with calretinin, CEA, and TTF-1: an optimal set of immunodiagnostic markers for pleural mesothelioma. Cancer. 2007;109:933-938.
37. Breiteneder-Geleff S, Soleiman A, Kowalski H, et al. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol. 1999;154:385-394.
38. Kahn HJ, Bailey D, Marks A. Monoclonal antibody D2-40, a new marker of lymphatic endothelium, reacts with Kaposi's sarcoma and a subset of angiosarcomas. Mod Pathol. 2002;15:434-440.